Health and environmental consequences of the World Trade Center disaster - Workgroup Report
Environmental Health Perspectives - May 1, 2004, by Philip J. Landrigan,
Paul J. Lioy,
George Thurston,
Gertrud Berkowitz,
L.C. Chen,
Steven N. Chillrud,
Stephen H. Gavett,
Panos G. Georgopoulos,
Alison S. Geyh,
Stephen Levin,
Frederica Perera,
The attack on the World Trade Center (WTC) created an acute environmental disaster of enormous magnitude. This study characterizes the environmental exposures resulting from destruction of the WTC and assesses their effects on health. Methods include ambient air sampling;... (Read More)
First drug for rare cancer - Updates - Alimta - Brief Article
FDA Consumer - May 1, 2004
Cancer of the mesothelium--a membrane that covers and protects most of the body's internal organs--is usually associated with a history of asbestos exposure and affects the lining of the chest. About 2,000 new cases are diagnosed each year. By the time symptoms appear, th... (Read More)
Human consumption of methyleugenol and its elimination from serum - Research
Environmental Health Perspectives - May 1, 2004, by Arnold Schecter,
George W. Lucier,
Michael L. Cunningham,
Kamal M. Abdo,
Greg Blumenthal,
Andrew G. Silver,
Ron Melnick,
Christopher Portier,
Dana B. Barr,
John R. Barr,
Stephen B. Stanfill,
&
Under a mandate from the U.S. Congress, the National Toxicology Program (NTP) of the U.S. Department of Health and Human Services conducts animal bioassays for carcinogenicity of potentially toxic chemicals to which the U.S. population might be exposed. Methyleugenol, a n... (Read More)
Salmedix Completes $45 Million Series C Financing
PR Newswire - March 30, 2004
SAN DIEGO, March 30 /PRNewswire/ -- Salmedix, Inc. announced today that it has completed the sale of $45 million of its Series C Preferred Stock.
New investor HIG Ventures led the round. Other new investors, OrbiMed Advisors, Easton Hunt Capital Partners, Hunt Venture... (Read More)
Salmedix, Inc. Presents Preclinical Data on Product Candidates at the American Association for Cancer Research Annual Meeting; Salmedix Founder Dennis
PR Newswire - March 25, 2004
SAN DIEGO, March 25 /PRNewswire/ -- Salmedix, Inc. announced today that company scientists and independent researchers will be presenting data supporting the potential anti-cancer activity of each of its three clinical- stage product candidates at the 95th Annual Meeting... (Read More)
Mesothelioma Applied Research Foundation Voices Continued Praise for 'Ban Asbestos in America Act'; Senate Press Conference Today Reaffirms Broad Support
PR Newswire - March 24, 2004
WASHINGTON, March 24 /PRNewswire/ -- The Mesothelioma Applied Research Foundation (MARF), the national organization dedicated to eradicating mesothelioma as a life-ending disease, today voiced its continued support for S.1115 -- the Ban Asbestos in America Act -- Sponsor... (Read More)
Hudson Health Sciences Announces Scientific Advisory Board Members
PR Newswire - March 23, 2004
SOUTH SAN FRANCISCO, Calif., March 23 /PRNewswire/ -- Hudson Health Sciences, Inc., a biopharmaceutical company headquartered in San Francisco, California announced today that six leading oncology scientists and clinical researchers have joined its Scientific Advisory Bo... (Read More)
Puget Sound Cancer Centers Plays Significant Role in Clinical Testing Of Newly Approved Cancer Drug; FDA Approves Alimta for Treatment of Asbestos-Related
Business Wire - March 16, 2004
News Editors/Health/Medical Writers
SEATTLE--(BUSINESS WIRE)--March 16, 2004
Puget Sound Cancer Centers was actively involved in the clinical testing for the new drug Alimta, the first approved treatment for asbestos-related cancer in patients who are not candidates f... (Read More)
Zengen, Inc.'s New Study Reviews Novel Approach to Control Inflammation Using Melanocortin Receptors
PR Newswire - March 3, 2004
WOODLAND HILLS, California, March 3 /PRNewswire/ --
- Study Supports Development Potential in Several Therapeutic Areas -
Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be... (Read More)
Zengen, Inc.'s New Study Reviews Novel Approach to Control Inflammation Using Melanocortin Receptors; - Study Supports Development Potential in Several
PR Newswire - March 3, 2004
WOODLAND HILLS, Calif., March 3 /PRNewswire/ -- Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be a novel strategy to control inflammatory disorders.
The findings, "Targetin... (Read More)
Video-assisted thoracoscopic surgery is a promising treatment for solitary fibrous tumor of the pleura - minimally invasive techniques
Chest - March 1, 2004, by Makoto Takahama,
Keiji Kushibe,
Takeshi Kawaguchi,
Michitaka Kimura,
Shigeki Taniguchi
Study objectives: Solitary fibrous tumors of the pleura (SFTPs) are slow-growing neoplasms. Approximately 800 cases have been reported in the literature to date. The aim of this study was to address our experience with the management of SFTPs and to evaluate the advantage... (Read More)
Other recent FDA approvals
Clinician Reviews - March 1, 2004
Zonegran[R] (zonisamide)--Elan Pharmaceuticals, Inc: In addition to the original 100-mg strength capsules, this adjunctive therapy for the treatment of partial seizures in adults with epilepsy is now available in 25-mg and 50-mg capsules. (zonegran.com) * Namenda[TM] (mem... (Read More)
|
